pISSN 1976-2283
eISSN 2005-1212

Cited by CrossRef (5)

  1. Gema Lledó, Laura Benítez-Gutiérrez, Ana Arias, Silvia Requena, Valentín Cuervas-Mons, Carmen de Mendoza. Benefits of hepatitis C cure with antivirals: why test and treat?. Future Microbiology 2019;14:425
    https://doi.org/10.2217/fmb-2019-0041
  2. Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology 2018;2018:1
    https://doi.org/10.1155/2018/6150861
  3. Daisuke Morihara, Yi‐Ling Ko, Kumiko Shibata, Ryo Yamauchi, Hiromi Fukuda, Naoaki Tsuchiya, Atsushi Fukunaga, Hideo Kunimoto, Hideyuki Iwashita, Kazuhide Takata, Takashi Tanaka, Kunitoshi Sakurai, Shinjiro Inomata, Keiji Yokoyama, Shinya Nishizawa, Yasuaki Takeyama, Makoto Irie, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka. IL28B gene polymorphism is correlated with changes in low‐density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct‐acting antiviral treatment . Journal of Gastroenterology and Hepatology 2019;34:2019
    https://doi.org/10.1111/jgh.14741
  4. Simone Lanini, Paola Scognamiglio, Raffaella Pisapia, Claudia Minosse, Alessandro Agresta, Giuseppe Ippolito. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. International Journal of Antimicrobial Agents 2019;53:559
    https://doi.org/10.1016/j.ijantimicag.2018.11.024
  5. Satoru Joshita, Ayumi Sugiura, Takeji Umemura, Tomoo Yamazaki, Naoyuki Fujimori, Akihiro Matsumoto, Yoko Usami, Eiji Tanaka. Clinical impact of normal alanine aminotransferase on direct‐acting antiviral outcome in patients with chronic hepatitis C virus infection. JGH Open 2019
    https://doi.org/10.1002/jgh3.12296